Discover how Mounjaro the revolutionary weight-loss and diabetes drug by Eli Lilly is set to transform obesity management in ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on December 9.Don't Miss Our ...